One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

Harry Thomasian, Jr. net worth and biography

Harry Thomasian, Jr. Biography and Net Worth

CFO of Precigen

Mr. Harry Thomasian Jr. serves as the Chief Financial Officer for Precigen. Mr. Thomasian is a global finance leader with over 35 years of international business experience in equity and debt financings, P&L management and business operations, regulatory compliance and generally accepted accounting principles, SEC filings and Sarbanes-Oxley compliance. Prior to joining the company, Mr. Thomasian was with EY (formerly Ernst & Young LLP), one of the world’s largest global professional services firms. He most recently served as Senior Client Services Partner and the Baltimore Office Growth Markets Leader for the life sciences industry and Senior Partner in EY’s Capital Markets Center in Tokyo as well as other various global, area and local leadership positions. Mr. Thomasian earned a BS in Accountancy from Bentley University and completed the Ernst & Young Executive Development Program at the Kellogg School of Management, Northwestern University. Mr. Thomasian is licensed as a certified public accountant by the State Boards of Accountancy in Maryland, North Carolina, Washington, DC and Virginia.

How do I contact Harry Thomasian, Jr.?: The corporate mailing address for Mr. Thomasian, Jr. and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Harry Thomasian, Jr.'s contact information.
Has Harry Thomasian, Jr. been buying or selling shares of Precigen?: Harry Thomasian, Jr. has not been actively trading shares of Precigen during the past quarter. Learn More on Harry Thomasian, Jr.'s trading history.
Who are Precigen's active insiders?: Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?: In the last year, Precigen insiders bought shares 4 times. They purchased a total of 641,097 shares worth more than $1,039,887.87. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 359,020 shares worth more than $513,769.48. The most recent insider tranaction occured on December, 28th when Director Randal J Kirk bought 96,686 shares worth more than $136,327.26. Insiders at Precigen own 41.7% of the company. Learn More about insider trades at Precigen.
Information on this page was last updated on 12/28/2023.

Harry Thomasian, Jr. Insider Trading History at Precigen

Harry Thomasian, Jr. Buying and Selling Activity at Precigen

Precigen Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Today's Range

Now: $1.41

$1.39

$1.44

50 Day Range

MA: $1.46

$1.31

$1.75

2 Week Range

Now: $1.41

$0.84

$1.88

Volume

241,103 shs

Average Volume

1,043,963 shs

Market Capitalization

$351.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>